How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Enhancing immunotherapy for the treatment of paediatric brain tumours
Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma
High-specificity killing of brain tumour cells using the Zika virus
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
‘Radiogenomics’: A novel non-invasive approach to identify different types of ependymoma brain tumours
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.
Developing a new understanding of the genetics of a rare lymphoma subtype
Identifying whether children with ALCL, ALK- also harbour other genetic changes in their tumours, and what affect this has on how their cancer progresses. This knowledge can help to guide clinicians about how best to treat children with this rarer sub-form of lymphoma.
Developing a ‘biodegradable paste’ to deliver chemotherapy directly to the brain to treat childhood brain tumours
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
Factors which affect survival following relapse in neuroblastomas
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
A novel laboratory model for neuroblastoma research
Establishment of an in vitro model of neuroblastoma initiation using pluripotent stem cell differentiation
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers